Belvedere Trading
QNCX icon

Belvedere Trading’s Quince Therapeutics QNCX Stock Holding History

Belvedere Trading’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60
Closed -$13.4K – 953
2023
Q3 		$13.4K Hold
60
– – ﹤0.01% 531
2023
Q2 		$18.1K Hold
60
– – ﹤0.01% 671
2023
Q1 		$18.7K Buy
+60
New +$11.7K ﹤0.01% 715
2021
Q4 		– Sell
-114
Closed -$1.34M – 586
2021
Q3 		$1.34M Buy
114
+64
+128% +$1.02M 0.04% 40
2021
Q2 		$578K Buy
+50
New +$419K 0.04% 95

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Belvedere Trading's QNCX Position: Q2 2026 in Review

Belvedere Trading sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 65 shares — an estimated $1.32K sold.

Belvedere Trading first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $1.32K in Q1 2026. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Belvedere Trading reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Belvedere Trading sold 65 Quince Therapeutics shares in Q2 2026, an estimated $1.32K.
  • Belvedere Trading first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
  • Belvedere Trading's Quince Therapeutics position peaked at $1.32K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.